KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:PHI1 - NL0000009538 - Common Stock
22.8 EUR
-0.09 (-0.39%)
Overall PHI1 gets a fundamental rating of 3 out of 10. We evaluated PHI1 against 62 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of PHI1 have multiple concerns. PHI1 has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PHI1 had positive earnings in the past year.
PHI1 had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
PHI1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of 0.61%, PHI1 is not doing good in the industry: 66.15% of the companies in the same industry are doing better.
PHI1 has a worse Return On Equity (1.56%) than 66.15% of its industry peers.
The Return On Invested Capital of PHI1 (4.00%) is worse than 61.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 1.56% | ||
| ROIC | 4% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 0.91%, PHI1 is doing worse than 66.15% of the companies in the same industry.
PHI1's Operating Margin of 6.11% is on the low side compared to the rest of the industry. PHI1 is outperformed by 60.00% of its industry peers.
In the last couple of years the Operating Margin of PHI1 has declined.
PHI1 has a worse Gross Margin (43.85%) than 76.92% of its industry peers.
In the last couple of years the Gross Margin of PHI1 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.11% | ||
| PM (TTM) | 0.91% | ||
| GM | 43.85% |
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
2. Health
2.1 Basic Checks
PHI1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PHI1 has less shares outstanding
PHI1 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for PHI1 is higher compared to a year ago.
2.2 Solvency
PHI1 has an Altman-Z score of 1.88. This is not the best score and indicates that PHI1 is in the grey zone with still only limited risk for bankruptcy at the moment.
PHI1's Altman-Z score of 1.88 is in line compared to the rest of the industry. PHI1 outperforms 41.54% of its industry peers.
PHI1 has a debt to FCF ratio of 19.41. This is a negative value and a sign of low solvency as PHI1 would need 19.41 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 19.41, PHI1 is doing worse than 60.00% of the companies in the same industry.
PHI1 has a Debt/Equity ratio of 0.69. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
The Debt to Equity ratio of PHI1 (0.69) is worse than 75.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 19.41 | ||
| Altman-Z | 1.88 |
ROIC/WACC0.63
WACC6.38%
2.3 Liquidity
PHI1 has a Current Ratio of 1.26. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.26, PHI1 is not doing good in the industry: 66.15% of the companies in the same industry are doing better.
PHI1 has a Quick Ratio of 1.26. This is a bad value and indicates that PHI1 is not financially healthy enough and could expect problems in meeting its short term obligations.
PHI1 has a worse Quick ratio (0.81) than 70.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.81 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.15% over the past year.
PHI1 shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.17% yearly.
The Revenue has decreased by -0.81% in the past year.
Measured over the past years, PHI1 shows a small growth in Revenue. The Revenue has been growing by 1.00% on average per year.
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
Revenue 1Y (TTM)-0.81%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%
3.2 Future
The Earnings Per Share is expected to grow by 13.05% on average over the next years. This is quite good.
Based on estimates for the next years, PHI1 will show a small growth in Revenue. The Revenue will grow by 3.41% on average per year.
EPS Next Y4.35%
EPS Next 2Y4.98%
EPS Next 3Y7.73%
EPS Next 5Y13.05%
Revenue Next Year-2.27%
Revenue Next 2Y0.25%
Revenue Next 3Y1.58%
Revenue Next 5Y3.41%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 15.41, the valuation of PHI1 can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of PHI1 indicates a rather cheap valuation: PHI1 is cheaper than 90.77% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.92. PHI1 is valued slightly cheaper when compared to this.
PHI1 is valuated correctly with a Price/Forward Earnings ratio of 14.93.
PHI1's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. PHI1 is cheaper than 72.31% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.46. PHI1 is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.41 | ||
| Fwd PE | 14.93 |
4.2 Price Multiples
72.31% of the companies in the same industry are more expensive than PHI1, based on the Enterprise Value to EBITDA ratio.
PHI1's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 50.59 | ||
| EV/EBITDA | 11.97 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHI1 does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)3.55
PEG (5Y)N/A
EPS Next 2Y4.98%
EPS Next 3Y7.73%
5. Dividend
5.1 Amount
No dividends for PHI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:PHI1 (12/23/2025, 7:00:00 PM)
22.8
-0.09 (-0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners44.69%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap21.95B
Revenue(TTM)18.02B
Net Income(TTM)162.00M
Analysts74.81
Price Target27.68 (21.4%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP0.62%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.64%
Min EPS beat(2)22.24%
Max EPS beat(2)31.04%
EPS beat(4)2
Avg EPS beat(4)6.19%
Min EPS beat(4)-16.56%
Max EPS beat(4)31.04%
EPS beat(8)3
Avg EPS beat(8)-1.09%
EPS beat(12)5
Avg EPS beat(12)15.29%
EPS beat(16)5
Avg EPS beat(16)3.51%
Revenue beat(2)0
Avg Revenue beat(2)-1.96%
Min Revenue beat(2)-1.97%
Max Revenue beat(2)-1.96%
Revenue beat(4)0
Avg Revenue beat(4)-3.05%
Min Revenue beat(4)-5.22%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.22%
Revenue beat(12)2
Avg Revenue beat(12)-1.61%
Revenue beat(16)2
Avg Revenue beat(16)-1.84%
PT rev (1m)0.1%
PT rev (3m)1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.38%
EPS NY rev (1m)4.1%
EPS NY rev (3m)3.91%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.41%
Revenue NY rev (1m)-0.35%
Revenue NY rev (3m)-0.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.41 | ||
| Fwd PE | 14.93 | ||
| P/S | 1.23 | ||
| P/FCF | 50.59 | ||
| P/OCF | 19.98 | ||
| P/B | 2.12 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.97 |
EPS(TTM)1.48
EY6.49%
EPS(NY)1.53
Fwd EY6.7%
FCF(TTM)0.45
FCFY1.98%
OCF(TTM)1.14
OCFY5.01%
SpS18.54
BVpS10.78
TBVpS-1.76
PEG (NY)3.55
PEG (5Y)N/A
Graham Number18.95
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.61% | ||
| ROE | 1.56% | ||
| ROCE | 5.69% | ||
| ROIC | 4% | ||
| ROICexc | 4.43% | ||
| ROICexgc | 14.55% | ||
| OM | 6.11% | ||
| PM (TTM) | 0.91% | ||
| GM | 43.85% | ||
| FCFM | 2.43% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y10.6%
ROICexgc growth 5Y-2.51%
ROICexc growth 3Y4.73%
ROICexc growth 5Y-6.98%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-Score8
Asset Turnover0.68
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.69 | ||
| Debt/FCF | 19.41 | ||
| Debt/EBITDA | 3.01 | ||
| Cap/Depr | 51.35% | ||
| Cap/Sales | 3.72% | ||
| Interest Coverage | 4 | ||
| Cash Conversion | 46.06% | ||
| Profit Quality | 267.9% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.81 | ||
| Altman-Z | 1.88 |
F-Score8
WACC6.38%
ROIC/WACC0.63
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.15%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%12.5%
EPS Next Y4.35%
EPS Next 2Y4.98%
EPS Next 3Y7.73%
EPS Next 5Y13.05%
Revenue 1Y (TTM)-0.81%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-1.71%
Revenue Next Year-2.27%
Revenue Next 2Y0.25%
Revenue Next 3Y1.58%
Revenue Next 5Y3.41%
EBIT growth 1Y476.21%
EBIT growth 3Y0.03%
EBIT growth 5Y-7.17%
EBIT Next Year48.95%
EBIT Next 3Y19.49%
EBIT Next 5YN/A
FCF growth 1Y3516.67%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y43.47%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%
KONINKLIJKE PHILIPS NV / PHI1.DE FAQ
What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.
What is the valuation status of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for KONINKLIJKE PHILIPS NV?
KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 2 / 10.
How financially healthy is KONINKLIJKE PHILIPS NV?
The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 2 / 10.
What is the earnings growth outlook for KONINKLIJKE PHILIPS NV?
The Earnings per Share (EPS) of KONINKLIJKE PHILIPS NV (PHI1.DE) is expected to grow by 4.35% in the next year.